BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) is a blank check company formed to pursue a business combination in the oncology and biopharmaceutical sector. The SPAC, which completed its initial public offering in 2024, is affiliated with management tied to BridgeBio Pharma's oncology franchise and targets acquisition opportunities in cancer therapeutics. The company filed an 8-K with the Securities and Exchange Commission on May 12, 2026, accession number 0001193125-26-219801, reflecting a reportable corporate event. As of the filing date, BBOT remains in the SPAC search phase pursuing a qualifying transaction. For complete filing history, deal timelines, and sponsor analytics on BBOT and hundreds of other SPACs, sign up for full data access at SpacDesk.